Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any mitochondrial complex deficiency in which the cause of the disease is a mutation in the ATP5F1D gene.
Features include always present findings: Lethargy, Decreased activity of mitochondrial ATP synthase complex, Hypoglycemia, and Hyperammonemia and others; and common findings: Bilateral tonic-clonic seizure, Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Ketoacidosis, and Delayed speech and language development and others. 20 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 6 |
ATP5F1D encodes ATP synthase F1 subunit delta (168 aa). Subunit delta, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). Highest expression in Muscle Skeletal (391.8 TPM) and Heart Atrial Appendage (290.9 TPM).
Mitochondrial complex V (ATP synthase) deficiency, nuclear type 5 is associated with mutations in the ATP5F1D gene on chromosome 19.
ATP5F1D is classified as a druggable target (Transporter category) with score 0.9.
Genetic testing for ATP5F1D is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 6 always present features, 12 common features.
No clinical trials have been registered for mitochondrial complex V (ATP synthase) deficiency, nuclear type 5.
4 publications have been identified in PubMed for mitochondrial complex V (ATP synthase) deficiency, nuclear type 5. Research spans Basic Science / Preclinical (50%), Review / Meta-Analysis (25%), and Case Report / Case Series (25%).
Panneerselvam K (2025). [PMID: 40855644](https://pubmed.ncbi.nlm.nih.gov/40855644/). *Proteomics*. [Review / Meta-Analysis]
İpek R (2025). [PMID: 40014158](https://pubmed.ncbi.nlm.nih.gov/40014158/). *Neurogenetics*. [Case Report / Case Series]
Fielder SM (2025). [PMID: 40672495](https://pubmed.ncbi.nlm.nih.gov/40672495/). *medRxiv*. [Basic Science / Preclinical]
Mulet I (2024). [PMID: 39557858](https://pubmed.ncbi.nlm.nih.gov/39557858/). *Nat Commun*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Lab test results | 3 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Decreased activity of mitochondrial ATP synthase complex, Elevated serum anion gap |
Muscles | 3 | Rhabdomyolysis, Ankle flexion contracture, Muscle weakness |
Growth and development | 1 | Short stature |
Heart and blood vessels | 1 | Enlarged and weakened heart (dilated cardiomyopathy) |